Drug Trial Radar · NCT03832452
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
Last checked: Nov 19, 2026Latest source record: Oct 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Feb 14, 2019
Primary completion
Apr 22, 2019
Study completion Apr 22, 2019
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)
Conditions
- Healthy
Interventions
Lucerastat (Treatment A)Drug
2000 and 4000 mg; hard capsules for oral administration
PlaceboOther
hard capsules for oral administration
MoxifloxacinDrug
400 mg; film-coated tablets for oral administration
Lucerastat (Treatment B)Drug
1000 mg; hard capsules for oral administration
Lucerastat (Treatment C)Drug
4000 mg; hard capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B: Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)Time frame: From 1 h pre-dose to 36 hour after study treatment administration (duration: up to 37 hours)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS Netherlands B.V.
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.